Freestone Grove Partners’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$653K Buy
7,017
+28
+0.4% +$2.48K ﹤0.01% 555
2025
Q4
$561K Buy
+6,989
New +$585K ﹤0.01% 553

Other funds holding ACLS

Freestone Grove Partners's ACLS Position: Q1 2026 in Review

Freestone Grove Partners increased its Axcelis (ACLS) stake by 0.4% in Q1 2026, buying an estimated $2.48K and bringing the position to 7,017 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #555.

Freestone Grove Partners first reported a position in ACLS in Q4 2025 and has held it in 2 quarters since. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • Freestone Grove Partners held 7,017 shares of Axcelis worth $653K as of Q1 2026.
  • Freestone Grove Partners bought 28 Axcelis shares in Q1 2026, an estimated $2.48K.
  • Axcelis made up ﹤0.01% of Freestone Grove Partners's portfolio in Q1 2026, its #555 holding.
  • Freestone Grove Partners first reported a position in Axcelis in Q4 2025 and has held it in 2 quarters since.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on Freestone Grove Partners's 13F filing for Q1 2026, filed 15 May 2026.